Phase 2 N=732 Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia
Schizophrenia
Primary: Change From Baseline to Week 6 in the PANSS Total Score — 97.3; 97.1; 97.2; 96.7 Units on a scale — p=0.0005
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=108 A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression
Treatment Resistant Depressive Disorder
Primary: Panel A and B: Change From Baseline (Day 1) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Day 8- Analysis of Covariance (ANCOVA) Analysis — -4.9…
Phase 1 N=94 A Phase 1 Study of LY2874455 in Participants With Advanced Cancer
Advanced Cancer
Primary: Recommended Dose for Phase 2 Studies : Maximum Tolerated Dose (MTD) — 16 mg
Phase 2 N=41 Secukinumab for Treatment of Atopic Dermatitis
Atopic Dermatitis
Primary: Fold-Change in Epidermal Thickness of Lesional Skin — 1.15; 1.5; 1.18; -1 fold-change
N/A N=170 BARD® The VENOVO™ Venous Stent Study for Treatment of Iliofemoral Occlusive Disease
May-Thurner Syndrome · Peripheral Vascular Disease · Venous Disease
Primary: Number of Participants With Primary Patency of the Venous Stent at 12 Months Post-Index Procedure — 128 Participants — p=0.0001
Phase 2 N=204 Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis
Pruritus · Psoriasis
Primary: WI-NRS 4-point Responder Rate at Week 8 — 33.29; 21.07 % of subjects (incl. imputed data)
Phase 2 N=22 A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma
Glioblastoma · Glioblastoma Multiforme
Primary: Median Overall Survival (OS) — 5.75 months
N/A N=31 Immunotherapy Administered Under the Tongue to Treat Dust Mite Allergy
Asthma
Primary: Bronchial Threshold to Allergen Challenge From Baseline to 12-18 Months of Treatment — 75.0; 69.5; 141.4; 74.8 cumulative breath units
N/A N=26 Titration Pressures in Sleep Apnea Patients Using ThermoSmart® Versus Conventional Humidification
Sleep Apnea, Obstructive
Primary: Titration Pressures After Treatment Nights — 9.8; 10.9 cmH20
Phase 2 N=54 Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance
Peanut Hypersensitivity · Food Hypersensitivity · Food Allergy
Primary: Population Sensitization Threshold in mg Peanut Protein Predicted to Provoke Reactions in 5% of the Peanut-allergic Population — 160; 300 mg
N/A N=1,495 PRediction of Opioid-induced Respiratory Depression In Patients Monitored by capnoGraphY
Respiratory Depression
Primary: Determine Number of Subjects With RD While on Opioid Therapy — 655; 840 Participants
N/A N=9 Magnetic Resonance (MR) Guided Focused Ultrasound Surgery of Uterine Fibroids
Leiomyoma
Primary: Number and Type of Adverse Events — 15 Adverse Events
Phase 3 N=457 Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
Psoriatic Arthritis
Primary: Proportion of Subject Who Reached (American College of Rheumatology Score of 20) ACR20 — 71.3; 73.9; 73.2; 73.6 percentage of participants
N/A N=1,065 The Effect of Different Financial Competing Interest Statements on Readers' Perceptions of Clinical Educational Articles
Healthy
Primary: The Readers' Level of Confidence in the Conclusions Drawn in the Article. — 6.2; 7.0; 6.1; 6.4 score on a scale
Phase 4 N=55 Pain Control in Pediatric Posterior Spine Fusion Patients: The Effect of Gabapentin
Pain, Postoperative
Primary: Difference in Pain Control When Adding Gabapentin to a Multimodal Pain Management Protocol in Pediatric Post-operative Posterior Spinal Fusion Patients. — 2.46; 3.46…